Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Revenue of Ocular Therapeutix, Inc. (OCUL)
Revenue in 2023 (TTM): $58.44 M
According to Ocular Therapeutix, Inc.'s latest financial reports the company's current revenue (TTM) is $58.44 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ocular Therapeutix, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $58.44 M | $53.16 M | $-66,415,000 | $-80,736,000 | $-80,736,000 |
| 2022 | $51.49 M | $46.95 M | $-61,907,000 | $-71,038,000 | $-63,422,000 |
| 2021 | $43.52 M | $39.12 M | $-75,616,000 | $-6,553,000 | $-10,804,000 |
| 2020 | $17.4 M | $15.32 M | $-146,095,000 | $-155,636,000 | $-159,631,000 |
| 2019 | $4.23 M | $1.9 M | $-77,741,000 | $-86,372,000 | $-89,935,000 |
| 2018 | $1.99 M | $1.53 M | $-55,953,000 | $-59,978,000 | $-57,692,000 |
| 2017 | $1.92 M | $1.47 M | $-59,869,000 | $-63,386,000 | $-63,386,000 |
| 2016 | $1.89 M | $1.44 M | $-42,142,000 | $-44,703,000 | $-44,703,000 |
| 2015 | $1.75 M | $1.43 M | $-37,270,000 | $-39,748,000 | $-39,748,000 |
| 2014 | $772 K | $681 K | $-26,982,000 | $-28,648,000 | $-28,648,000 |
| 2013 | $ | $-10,517,000 | $-12,499,000 | $-13,317,000 | $-13,317,000 |
| 2012 | $10 K | $3 K | $-13,312,000 | $-14,093,000 | $-14,093,000 |